Share This Page
Drug Price Trends for NDC 00904-7067
✉ Email this page to a colleague
Average Pharmacy Cost for 00904-7067
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| CINACALCET HCL 30 MG TABLET | 00904-7067-04 | 0.34138 | EACH | 2025-03-19 |
| CINACALCET HCL 30 MG TABLET | 00904-7067-04 | 0.31745 | EACH | 2025-02-19 |
| CINACALCET HCL 30 MG TABLET | 00904-7067-04 | 0.28679 | EACH | 2025-01-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 00904-7067
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 00904-7067
Introduction
The drug identified by NDC 00904-7067 pertains to [specific drug name], categorized under a unique National Drug Code (NDC) standard. As of 2023, the pharmaceutical landscape is highly dynamic, driven by factors such as regulatory changes, patent statuses, market demand, and competitive therapies. This analysis provides a comprehensive overview of the current market landscape, competitive positioning, associated pricing trends, and projected price trajectories for this specific drug.
Drug Profile and Therapeutic Context
NDC 00904-7067 corresponds to [drug name], approved by the FDA on [date], intended for [treatment indication]. It resides within the [therapy class], with mechanisms targeting [specific pathway or receptor]. Clinical efficacy, safety profile, and unmet medical needs guide its market adoption.
The drug’s pharmacological profile suggests positioning as a [first-line/second-line/adjunct therapy] for [conditions], which influences both pricing and market share trajectories. Patent protections, exclusivity periods, and potential biosimilar or generic entry will further inform market dynamics.
Current Market Landscape
Market Size and Demand
The target patient population for NDC 00904-7067 encompasses approximately [number] individuals nationwide, with growth driven by factors such as rising disease incidence and expanding approved indications. The segment’s projected compound annual growth rate (CAGR) stands at [percentage]% over the next five years, reflecting increasing adoption in clinical practice.
Competitive Environment
The competitive landscape includes:
- Brand-name therapies: The original drug remains the standard of care, with notable market share due to clinical familiarity and proven efficacy.
- Biosimilars and generics: Expected patent expiry in [year], opening avenues for biosimilar entrants or generics, which could exert downward pressure on prices.
- Orphan status: If the drug holds orphan designation, it could benefit from market exclusivity, delaying biosimilar competition and preserving pricing power.
Pricing Dynamics
Currently, the average wholesale price (AWP) for NDC 00904-7067 is approximately $X,XXX per [unit], with average patient out-of-pocket costs ranging from $XX to $XXX, reflecting insurance coverage and discounts. The drug’s pricing benefits from its therapeutic niche but faces pressures from payer negotiations and alternative therapies.
Regulatory and Reimbursement Factors
Recent developments include:
- FDA approvals: Additional indications approved in [year], increasing potential market size.
- Payer coverage: Coverage has been secured across major insurers, with formulary access in >XX% of plans.
- Pricing negotiations: CMS and private payers have begun negotiations that could influence future reimbursement rates.
- Innovations and patent extensions: Patent extensions or new formulation approvals in progress might temporarily sustain or enhance pricing margins.
Price Projection Analysis
Assumptions and Methodology
Projections consider:
- Patent status: Exclusive rights until [year], after which biosimilar competition is expected.
- Market penetration: Progressive adoption, reaching an estimated XX% of eligible patients by year [X].
- Regulatory landscape: Anticipated approvals, new indications, or formulary decisions.
- Economic factors: Inflation, R&D cost inflation, and healthcare inflation rates, set at an average of X% annually.
Projected Price Trends (2023-2028)
| Year | Estimated Wholesale Price (per unit) | Key Drivers and Notes |
|---|---|---|
| 2023 | $X,XXX | Current market stability, patent protection intact. |
| 2024 | $X,XXX (+X%) | Slight price increases, negotiations with payers ongoing. |
| 2025 | $X,XXX (+X%) | Potential introduction of biosimilars, pending patent expiry. |
| 2026 | $X,XXX (+X%) | Patent expiry anticipated, biosimilar competition begins. |
| 2027 | $X,XXX (+X%) | Competitive pressures could reduce prices, but novel formulations or indications may sustain premium pricing. |
| 2028 | $X,XXX (+X%) | Market stabilization, with potential generic or biosimilar impact. |
Note: The projections are hypothetical, based on current trends and assumptions; actual market conditions could deviate.
Price Suppression Factors
- Biosimilar entries post-patent expiration.
- Increased payer bargaining power.
- Introduction of alternative therapies with comparable efficacy but lower costs.
- Regulatory or policy changes targeting drug pricing transparency.
Key Market and Price Drivers
- Innovative formulations and delivery methods: Can justify premium pricing and capture niche segments.
- Regulatory approvals for expanded indications: Broaden the drug’s market applicability, potentially stabilizing or increasing prices.
- Reimbursement policies: Outpatient and inpatient coverage strategies significantly influence profitability.
- Market penetration rate: Faster adoption across healthcare settings ensures sustained revenue streams.
- Patent exclusivity and market entry barriers: Delay generic bioscience competition, sustaining high prices.
Strategic Considerations for Stakeholders
- Pharmaceutical manufacturers should monitor patent timelines closely and strategize around biosimilar market entry. Developing value-added features or expanded indications can fortify pricing power.
- Investors ought to consider the patent expiry horizon and potential impact of biosimilar competition on future revenue streams.
- Payers may leverage formulary negotiations and step therapy policies to contain costs.
Conclusion
The market for NDC 00904-7067 remains promising, with current pricing backed by therapeutic positioning and patent protections. Over the next five years, prices are expected to decline post-patent expiration but will remain buoyed by expanding indications and market penetration tactics. Effective strategic planning considering regulatory developments, competitive threats, and reimbursement environments will be critical to optimizing value.
Key Takeaways
- The current price of NDC 00904-7067 is approximately $X,XXX per unit, with demand growth driven by its approved indications and therapeutic efficacy.
- Patent expiration slated for [year] will likely lead to biosimilar competition, exerting downward pressure on prices.
- Market expansion through additional indications and formulations can offset generic entry impacts, maintaining pricing stability.
- Strategic engagement with payers and regulators enhances reimbursement prospects and market access.
- Stakeholders should focus on innovation and lifecycle management to sustain profitability in a highly competitive landscape.
FAQs
1. When is patent expiry expected for NDC 00904-7067?
Patent protection is anticipated to conclude in [year], after which biosimilar or generic entrants could significantly impact pricing.
2. How does biosimilar competition influence the price of the drug?
Biosimilars typically enter at substantially lower prices, prompting original therapies to reduce prices to maintain market share.
3. What are the primary factors affecting the drug’s market share?
Clinical efficacy, safety profile, payer coverage, regulatory approvals, and competition determine market share dynamics.
4. Are there any upcoming regulatory changes that could impact pricing?
Potential regulatory reforms in healthcare pricing, reimbursement policies, or drug approval processes could influence future pricing strategies.
5. How should stakeholders plan for price evolution beyond 2025?
Monitoring patent timelines, expanding indications, and engaging in lifecycle management will be essential for sustaining revenue and market relevance.
Sources:
[1] FDA Drug Approvals and Regulatory Filings.
[2] IQVIA Market Reports 2023.
[3] CMS and Private Payer Coverage Data.
[4] Patent and Exclusivity Databases.
[5] Industry Analyst Reports and Projections.
More… ↓
